All In MedTech

Device Trial Radar · NCT04142658

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban

Last checked: Nov 20, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 863 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

863

Actual

Start

May 1, 2020

Primary completion

Dec 12, 2022

Study completion Dec 12, 2022

Sponsor

Lead sponsor
Artivion Inc.Public (AORT)
Sponsor type
Industry
Collaborators
Duke Clinical Research Institute
First posted
Oct 29, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Currently, warfarin is the only approved anticoagulation for patients with mechanical valves. The purpose of this study is to determine if participants with an On-X Prosthetic Heart Valve / On-X aortic valve can be maintained safely and effectively on apixaban. Both the On-X aortic valve and apixaban have been approved for use by the US Food and Drug Administration (FDA) but they have not been approved to be used together.

Conditions

  • Aortic Valve Disease
  • Aortic Valve Stenosis
  • Aortic Valve Failure

Interventions

  • Apixaban 5 MGDrug

    For patients that do NOT meet the following criteria * age ≥ 80 years * weight ≤ 60 kilograms * creatinine ≥ 1.5 mg/dL (133 micromol/L)

  • Apixaban 2.5 MGDrug

    For patients that meet at least 2 of the following criteria * age ≥ 80 years * weight ≤ 60 kilograms * creatinine ≥ 1.5 mg/dL (133 micromol/L)

  • WarfarinDrug

    Active Control Intervention

  • On-X Aortic Mechanical ValveDevice

    Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Valve Thrombosis and Valve-related ThromboembolismTime frame: through study closure, a median follow-up of 13.5 months
  2. Major BleedingTime frame: through study closure, a median follow-up of 13.5 months

Locations

62 sites in 1 country. Site status is shown where the registry gives one.

  • Tucson Heart Center

    Tucson, Arizona

  • CHI St. Vincent Heart Institute

    Little Rock, Arkansas

  • Loma Linda University Medical Center

    Loma Linda, California

59 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.